The journal «Practical oncology» / Т.19, №2, 2018, Lung cancer

MOLECULAR TARGETS IN LUNG CANCER: CURRENT STATUS

Authors: 

DOI: https://www.doi.org/10.31917/1902093
Abstract:

Lung cancer (LC) is the most frequent oncological disease worldwide. Treatment
opportunities may significantly depend on the smoking status of the patients. LC in
non-smokers are characterized by elevated frequency of EGFR, ALK, ROS1, RET, MET
and BRAF mutations. There are highly effective inhibitors for each of the mentioned
mutated kinases. Mutations in the above genes are significantly less common in
smoking-induced LCs. However, LCs arising in smokers usually demonstrate high
mutation burden and therefore have increased responsivity to immune checkpoint modulators. LC is the first solid tumor for which molecular diagnosis began to be utilized not only at the start of the
treatment, but also during the course of therapy. Patients with EGFR-mutated LC progressing on gefitinib, erlotinib or afatinib are to be tested for EGFR T790M mutation, with subsequent administration of osimertinib in T790M-positive cases. Liquid biopsy utilizing circulating tumor DNA is being increasingly used for LC monitoring.

Download